MNPR
Monopar Therapeutics Inc. Common Stock
Nasdaq · usd
Monopar Therapeutics Inc. Common Stock (MNPR) trades at $70.16 (-0.69%) as of 2:23:05 PM EDT on Oct 26, 2026, -17.50% over the past month. Market cap is $474.21M, with 6.0 days to cover in short interest.
Stock performance
How Monopar Therapeutics Inc. Common Stock (MNPR) stock has performed from one day to one year, with its 52-week range.
- 1D
- -0.47%
- 1W
- -1.61%
- 1M
- -17.50%
- YTD
- +7.69%
- 1Y
- -13.44%
- 52-wk range
- $50.07 – $124.82
Key statistics
Today's trading snapshot for MNPR: day range, open, previous close, volume and market cap.
- Day range
- $69.34 – $71.85
- Open
- $71.01
- Prev close
- $70.65
- Volume
- 46.86K
- Market cap
- $474.21M
- Shares out
- 6.71M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Monopar Therapeutics Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 3.62
- P/FCF
- —
- ROE
- -13.6%
- ROA
- -13.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Monopar Therapeutics Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Regulatory decisionJun 30, 2026
On June 30, 2026, Monopar Therapeutics Inc. ("Monopar") issued a press release announcing that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline).
- Clinical trial resultsJun 26, 2026
Monopar issued a press release announcing the presentation of new analyses from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) showing greater neurologic and global clinical benefit versus standard of care in Wilson disease patients.
- Clinical trial resultsMay 29, 2026
Monopar presented results from a Phase 2 study (NCT04422431) evaluating the effect of ALXN1840 (tiomolibdate choline) on liver pathology and clinical symptoms in patients with Wilson disease at the European Association for the Study of the Liver (EASL) International Liver Congress 2026.
- Clinical trial resultsMay 19, 2026
Monopar issued a press release announcing the presentation of results from the Phase 2 ALXN1840-WD-204 study demonstrating that ALXN1840 (tiomolibdate choline) improves copper balance in patients with Wilson disease.
- Clinical trial resultsApr 20, 2026
Monopar issued a press release announcing the presentation of new analyses from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) showing greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms at baseline.
Dividend history and stock splits
Monopar Therapeutics Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-5Aug 13, 2024
MNPR short interest
How heavily MNPR is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.0
- Short interest
- 1.09M
- Avg volume
- 180.45K
As of · reported to FINRA twice monthly.
MNPR news
The latest news and headlines about Monopar Therapeutics Inc. Common Stock (MNPR).
- Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026positiveGlobeNewswire Inc.· Jun 1, 2026
- Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatespositiveGlobeNewswire Inc.· May 14, 2026
- Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdatepositiveGlobeNewswire Inc.· Mar 27, 2026
- Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025positiveGlobeNewswire Inc.· Nov 9, 2025
- Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsneutralGlobeNewswire Inc.· Sep 23, 2025
Frequently asked questions
What is the Monopar Therapeutics Inc. Common Stock (MNPR) stock price today?
Monopar Therapeutics Inc. Common Stock (MNPR) is trading at $70.16 (-0.69% on the day) as of 2:23:05 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Monopar Therapeutics Inc. Common Stock?
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine.
What is the short interest in MNPR?
As of Sep 30, 2026, MNPR has 1.09M shares short and 6.0 days to cover.
What exchange is MNPR listed on?
Monopar Therapeutics Inc. Common Stock (MNPR) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of MNPR with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a MNPR analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.